INTRODUCING FARON

Faron Pharmaceutical is a clinical-stage biopharmaceutical company based in Finland and the United States ~~in the US,~~ with a focus on developing bexmarilimab, a first-in-class, humanized antibody that binds the CLEVER-1 target on myeloid cells and macrophages.

CLEVER-1 is an immunosuppressive receptor ~~on macrophages~~ ~~leading to~~ that promotes tumor growth and metastases when expressed on macrophages. Bexmarilimab primes the tumor microenvironment for optimal antitumor immune responses, in both hematological malignancies and solid tumors. ~~We are dedicated to finding solutions through immunotherapy to improve patient outcomes.~~*Already states this above on webpage*

“~~In 2022, we saw~~ We continue to see impressive growth in our bexmarilimab program, with exciting early data across both hematologic malignancies and solid tumors. These accomplishments could not have been done without the continued support of our shareholders and the incredible team at Faron. We have a bright future ahead and I’d like to thank everyone for their dedication to fighting cancer and improving patient outcomes.”

OUR SCIENCE

Bexmarilimab targets tumor-associated macrophages (TAMs) expressing the Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) ~~positive tumor-associated macrophages (TAMs), which are expressed on certain immune cells~~ in the tumor microenvironment (~~TMI~~TME). TAMs are considered a key source of resistance to current standard of care.

Bexmarilimab is designed to reprogram~~s~~ ~~these~~highly immunosuppressive M2 macrophages to immune-stimulating M1 macrophages, priming the ~~TMI~~TME optimal antitumor immune responses and sensitizing it to available therapies. Bexmarilimab is in the Phase I/II MATINS study as a monotherapy in solid tumors and in the Phase I/II BEXMAB trial for hematological malignancies in combination with standard of care.

**ABOUT US Page:**

<https://faron-corp.sid2-e1.investis.com/about-us>

INTRODUCING FARON

We are a clinical-stage Finnish and American biopharmaceutical company focused developing an innovative ~~therapy~~therapies to modulate the immune system to tackle cancer and improve patient lives.

**Bexmarilimab Page:**

<https://faron-corp.sid2-e1.investis.com/our-science/bexmarilimab>

BEXMAB

Title here be Bemarilimab, instead of title of specific trial

**Investor Relations Page:**

<https://faron-corp.sid2-e1.investis.com/investors>

Find out more about our shares, financial data, and read through our financial reports.

*Add -s to share*

WHY INVEST IN FARON

We are developing a new, unique cancer drug.

We have tested the drug in over 200 cancer patients that have no treatment option left and face death. We have shown that the drug is well tolerated and not toxic like chemotherapy. We have shown that 1 out of 3 patients with gastric cancer, liver cancer, melanoma, bile duct cancer or breast cancer benefit from the drug and that we can stabilize the progression of cancer. These patients live 3 times longer than the patients that do not benefit from the drug.